Glutamate is a non-invasive metabolic biomarker of IDH1 mutant glioma response to temozolomide treatment

Although lower-grade gliomas are driven by mutations in the isocitrate dehydrogenase 1 (IDH1) gene and are less aggressive than primary glioblastoma, they nonetheless generally recur. IDH1 mutant patients are increasingly being treated with temozolomide (TMZ), but early detection of response remains...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Res
Main Authors: Subramani, Elavarasan, Radoul, Marina, Najac, Chloe, Batsios, Georgios, Molloy, Abigail R., Hong, Donghyun, Gillespie, Anne Marie, Santos, Romelyn Delos, Viswanath, Pavithra, Costello, Joseph F., Pieper, Russell O., Ronen, Sabrina M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7669718/
https://ncbi.nlm.nih.gov/pubmed/32958546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-20-1314
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados